Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD-1/PD-L1 Inhibitor and Chemotherapy With/Without Microwave Intervention in Central NSCLC
NCT04360655Unknown
- Sponsor
- Shanghai Pulmonary Hospital
- Start
- May 2020
- Primary completion
- Apr 2022
01
Overview
Randomised trial in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Shanghai Pulmonary Hospital. Primary endpoints: Objective Response Rate at 6 weeks and Progression-Free Survival at 1 year. Status: unknown.
02
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04360655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04360655.